In the last 10 years, from 2013 to 2023, fourteen original articles have investigated the efficacy of IFNα in patients with CHD (Anastasiou et al., 2024; Karaca et al., 2013; Abbas et al., 2014; Heller et al., 2014; Keshvari et al., 2014; Bahcecioglu et al., 2015; Abbas et al., 2016; Borzacov et al., 2016; Niro et al., 2016; Soyer et al., 2016; Wranke et al., 2017; Boglione et al., 2019; Wedemeyer et al., 2019b; Etzion et al., 2023), both clinical trials and real-life studies. The gene discussed is IFNA1; the disease is coronary artery disorder.